Table 2.

Radiographic, tumor, and molecular characteristics by care pathway

Characteristic	Overall (N = 166)	Urgent (n = 122)	Scheduled (n = 44)	p value
Radiographic / tumor
Eloquent location	88 (53)	62 (51)	26 (59)	0.382
Max tumor diameter, mm	44.5 [10–87]	48 [10–87]	36 [10–69]	< 0.001
Midline shift	90 (54)	76 (62)	14 (32)	< 0.001
Multifocal disease	33 (20)	23 (19)	10 (23)	0.660
Tumor location				0.939
Multilobar	51 (31)	37 (30)	14 (32)	0.851
Frontal	46 (28)	33 (27)	13 (30)	0.845
Temporal	43 (26)	31 (25)	12 (27)	0.842
Parietal	19 (11)	15 (12)	4 (9.1)	0.783
Occipital	3 (1.8)	3 (2.5)	0 (0)	0.566
Insular	2 (1.2)	1 (0.8)	1 (2.3)	0.461
Cerebellar	1 (0.6)	1 (0.8)	0 (0)	1.000
Other	1 (0.6)	1 (0.8)	0 (0)	1.000
Pathology & molecular
WHO grade, IDH status, and histologic diagnosis
Grade 4, IDH-wildtype	152 (92)	115 (94)	37 (84)
Glioblastoma	144 (87)	108 (89)	36 (82)
Gliosarcoma	3 (1.8)	3 (2.5)	0 (0)
Other HGG	3 (1.8)	3 (2.5)	0 (0)
Astrocytoma	2 (1.2)	1 (0.8)	1 (2.3)
Grade 4, IDH-mutant	3 (1.8)	2 (1.6)	1 (2.3)
Astrocytoma	3 (1.8)	2 (1.6)	1 (2.3)
Grade 3, IDH-mutant	8 (4.8)	4 (3.3)	4 (9.1)
Astrocytoma	5 (3.0)	2 (1.6)	3 (6.8)
Oligodendroglioma	3 (1.8)	2 (1.6)	1 (2.3)
Grade 3, IDH-wildtype	3 (1.8)	1 (0.8)	2 (4.5)
Astrocytoma	2 (1.2)	1 (0.8)	1 (2.3)
Other HGG	1 (0.6)	0 (0)	1 (2.3)
WHO grade 4	155 (93)	117 (96)	38 (86)	0.069
IDH-mutant	11 (6.6)	6 (4.9)	5 (11)	0.162
MGMT methylated	71/154 (46)	51/113 (45)	20/41 (49)	0.718

Histologic diagnosis is the label on the pathology report; under the 2021 WHO classification, all IDH-wildtype grade 4 tumors (n = 152) are glioblastoma. MGMT was untested in 12 patients; methylation percentages use the tested denominator. IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine-DNA methyltransferase; WHO, World Health Organization